| Company Name: |
EMMX Biotechnology LLC
|
| Tel: |
888-539-0666 |
| Email: |
info@emmx.com |
| Products Intro: |
Product Name:W146
CAS:909725-62-8
Purity:98% HPLC Package:5mg;10mg;25mg;50mg;100mg;250mg;500mg;1g
|
| Company Name: |
Codow Chemical Co.,Ltd.
|
| Tel: |
18620099427 |
| Email: |
amy@howeipharm.com |
| Products Intro: |
Product Name:(R)-3-Amino-(3-hexylphenylamino)-4-oxobutylphosphonic acid (TFA salt)
CAS:909725-62-8
Purity:>99% Package:1MG;2.5MG;5MG
|
| Company Name: |
Chengdu Dianchun Technology Co., Ltd
|
| Tel: |
400-1166-196 18502815961 |
| Email: |
cdhxsj@163.com |
| Products Intro: |
Product Name:(R)-3-Amino-(3-hexylphenylamino)-4-oxobutylphosphonic acid (TFA salt)
CAS:909725-62-8
Purity:99% HPLC Package:10g;50g;100g;500g;1kg;5kg;25kg
|
|
| | [(3R)-3-Amino-4-[(3-hexylphenyl)amino]-4-oxobutyl]-phosphonic acid mono(trifluoroacetate) Basic information |
| | [(3R)-3-Amino-4-[(3-hexylphenyl)amino]-4-oxobutyl]-phosphonic acid mono(trifluoroacetate) Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Methanol: 0.1 mg/ml | | form | A crystalline solid | | color | White to off-white |
| | [(3R)-3-Amino-4-[(3-hexylphenyl)amino]-4-oxobutyl]-phosphonic acid mono(trifluoroacetate) Usage And Synthesis |
| Uses | W146 is a selective antagonists of spingosine-1-phosphate receptor subtype 1. | | Biological Activity | W146 acts as an orthosteric antagonist. It is linked to blood lymphopenia and lung edema in mice. | | in vivo | W146 (5 mg/kg, ip, prior to AMD3100 administration) pre-treatment shows approximately 8-fold increase of KSL-HSPC mobilization, measured by the CFU-G/M colony forming assays, compared to that in mice treated with AMD3100 alone[3]
The W146-mediated augmentation of KSL-HSPC mobilization is specific, because pretreatment of mice with W140 is unable to produce any effect on AMD3100-stimulated KSL-HSPC mobilization. Injections of W146, W140, JTE013, or Cay10444 do not alter the basal WBC count in mice[3]. | Animal Model: | Mice (4-6-week-old)[3]
. | | Dosage: | 5 mg/kg. | | Administration: | IP, 1 hour prior to AMD3100 (ADM) administration. | | Result: | Significantly increased in KSL-HSPC mobilization compared to that in mice pretreated with dextran followed by AMD3100 administration. |
|
| | [(3R)-3-Amino-4-[(3-hexylphenyl)amino]-4-oxobutyl]-phosphonic acid mono(trifluoroacetate) Preparation Products And Raw materials |
|